The CDC Influenza Reagent Resource (IRR) was established in 2008 to provide critical reagents to laboratories around the world that participate in the WHO/CDC influenza surveillance network. ATCC provides:

• The manufacturing, QC, authentication, assembly, storage and distribution of flu viruses, test kits, and reagents for labs that need them on an ongoing basis.
• A secure web portal that allows participating researchers to get the correct viral strains, kits and reagents.

Because of the continued threat of an influenza pandemic, ATCC and its partners have prepared a pandemic response plan to handle increased demand in a time of crisis. In response to the Novel H1N1 pandemic, ATCC rapidly assembled and distributed IVD H1N1 and seasonal influenza test kits, including components requiring GMP Manufacturing.

The Biodefense and Emerging Infections Resources Program (BEI Resources) is one of the largest, most diverse publicly accessible infectious disease and biodefense reagent repositories. BEI Resources was established by NIAID at ATCC in 2003 to leverage our extensive expertise in acquiring, authenticating, preserving and distributing regulated infectious disease materials, including Select Agents, BSL-3 organisms and their derivatives.

ATCC is perfectly poised to help make your organization's infectious disease and biodefense goals and objectives more readily attainable.

• BEI Resources reflects a coordinated effort by NIAID and ATCC to support and promote HHS research initiatives and collaborations between other federal agencies including DHS, DoD, CDC and their industry and academic partners.
• The collection of reference reagents housed in BEI Resources has rapidly grown to over 20,000 unique items available to scientists developing novel and improved diagnostic tests, vaccines and therapeutic counter measures.
• BEI Resources is supported by five BSL-3 laboratory suites, vast storage and distribution capability and capacity and extensive scientific and biomaterials management competencies.

CDC and ATSDR Specimen, Packaging, Inventory & Repository (CASPIR) was established in 1997 to provide a state-of-the-art biologic specimen storage facility that includes a high quality inventory management system for timely entry and retrieval of biological and environmental specimens.  ATCC staff at the CDC facility provide a variety of services.

ATCC currently manages over 4.5 million specimens in the CASPIR collections.

• Efficient management of specimen aliquoting, labeling, storing, and shipping.
• Expert advice on specimen handling, barcoding, tracking, and inventory management.
• Enforcement of required security measures and maintenance of specimen management database.
• Management of historical and epidemiological collection data.
• Production of routine and ad hoc specimen reports for CDC laboratorians and researchers.

The Malaria Research and Reference Reagent Resource Center (MR4) was established by NIAID in 1998 to provide malaria-related reagents and information to the international malaria research community.

ATCC’s work has allowed more than 800 laboratories in 68 countries worldwide to participate in MR4 since its inception and more than 1,700 MR4 malaria reagents are distributed annually.

• Acquiring, amplifying, authenticating, preserving, developing, and distributing human and animal malaria parasites, mosquito vectors and supporting molecular and immunological research reagents.

• Developing, proctoring and consulting in international workshops on wide-ranging malaria and laboratory related topics.
• Recruiting, developing, testing, compiling and disseminating research protocols and assays to the community.
• Organizing and running an international Scientific Advisory Committee that provides oversight of the MR4 operations, helps prioritize reagent acquisition and training needs, and acts as a liaison to the malaria community.

The NCI contract for the Procurement of Transformed Lymphocytes, Lymphoblastoid Cell Lines and DNA for Genetic Linkage Studies was established in 1990. The reagents prepared under this contract are used to conduct studies on individuals with cancer or who are at risk of developing cancer.

• Isolation of DNA from fresh whole blood specimens, transformed lymphoblastoid lines, cultured fibroblasts, tumor specimens, buccal cells, paraffin-embedded tissue and other biological specimens.

• Isolation of RNA from fresh whole blood specimens, transformed lymphoblastoid lines, cultured fibroblasts, tumor specimens.
• Transformation of fresh or cryopreserved lymphocytes; fresh or cryopreserved whole blood to lymphoblastoid cells using the Epstein-Barr virus (EBV).
• Expansion of lymphoblastoid or other cell lines up to gram quantities.